Compounds > sekdel sequence
Page last updated: 2024-11-07

sekdel sequence

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SEKDEL sequence: signal which leads to retention of at least two proteins in the endoplasmic reticulum of animal cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID130073
SCHEMBL ID17099905
MeSH IDM0171922

Synonyms (11)

Synonym
sekdel sequence
123924-38-9
ser-glu-lys-asp-glu-leu
seryl-glutamyl-lysyl-aspartyl-glutamyl-leucine
l-leucine, n-(n-(n-(n2-(n-l-seryl-l-alpha-glutamyl)-l-lysyl)-l-alpha-aspartyl)-l-alpha-glutamyl)-
SCHEMBL17099905
2-amino-8-(4-aminobutyl)-5-(2-carboxyethyl)-11-(carboxymethyl)-14-{[(1-carboxy-3-methylbutyl)imino](hydroxy)methyl}-1,3,6,9,12-pentahydroxy-4,7,10,13-tetraazaheptadeca-3,6,9,12-tetraen-17-oic acid
DTXSID90924640
(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoic acid
(2s,5s,8s,11s,14s)-14-((s)-2-amino-3-hydroxypropanamido)-11-(4-aminobutyl)-5-(2-carboxyethyl)-8-(carboxymethyl)-2-isobutyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazaheptadecanedioic acid
AKOS040753998
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's4 (57.14)18.2507
2000's2 (28.57)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.77 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
g(m1) ganglioside
G(M1) Ganglioside: A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis.. ganglioside GM1 : A sialotetraosylceramide consisting of a branched pentasaccharide made up from one sialyl residue, two galactose residues, one N-acetylgalactosamine residue and a glucose residue at the reducing end attached to N-stearoylsphingosine via a beta-linkage.		2.0510alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine;
sialotetraosylceramide
lactoferrin
Lactoferrin: An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion.		210
ConditionIndicatedRelationship StrengthStudiesTrials
Kahler Disease
[description not available]		01.9910
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		01.9910
Hepatocellular Carcinoma
[description not available]		0210
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		0210